Trabalhos Científicos

Buscar
Para realizar uma busca personalizada, utilize os filtros abaixo:
Título
Autor
*é possível selecionar mais de uma opção.
*é possível selecionar mais de uma opção.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Limpar busca
Resultado
100
de
100
trabalhos

Oncological Navigation and the Assessment of Barriers in the Continuum of the Oncological Journey

Local
Área Exposição Pôster - 3º andar
Código
2084
Dia / Horário
9-nov.
/
10:15 - 10:53
Autor Responsável
Claudia Cristina Klumpp
Tema
Nursing in Clinical Oncology
Forma de apresetação
Pôster
Autores
Claudia Cristina Klumpp , Thais Zilles Fritsch , Janaina Santos Paulista , Larissa de Mello Kuil , Amanda Desidera , Mayara Marinho Ferreira , Larissa Dias Figueiredo Castanon , Ana Paula Gomes de Lacerda , Tailine Ligia Tadini da Rocha , Ariane Silva da Rocha , Alex Godoy da Silva , Jessica Chiconi de Andrade Silva , Arildo Pimentel Mendes , Luiza da Costa Paiva , Fernanda Fachetti Xavier de Almeida , Lara Cinthia Mitsuko Etho , Gisele Polotow do Nascimento
Instituições dos autores (EM ordem)
ACCamargo Cancer Center , ACCamargo Cancer Center , AC Camargo Cancer Center , AC Camargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center , AC Camargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center , AC Camargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center , ACCamargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center , A C Camargo Cancer Center
Resumo
Introduction: Oncology patients undergo significant changes in their routines, impacting access to and management of their treatment journey. The nurse navigator (NN) plays a crucial role in identifying and overcoming barriers, particularly during the initial nursing consultation. Objective: To analyze the barriers faced by oncology patients during the initial consultation with the NN in a navigation program (NP) at a Cancer Center. Method: A retrospective cross-sectional study, approved by the Research Ethics Committee (CAAE: 47748821.7.0000.5432). Data collected between October 2021 and March 2024 were analyzed in absolute numbers, percentages, and through the cross-referencing of sociodemographic variables and barriers. Results: A total of 9,083 patients were analyzed, with 58% being female and most aged between 50-69 years. Although most patients did not present significant communication, diagnosis understanding, or transportation barriers, patients over 70 years old (26%) showed greater difficulty in understanding their diagnosis and treatment (p<0.0001). Additionally, 44.4% of patients reside outside the city of São Paulo, facing geographical barriers to treatment access. Low education (8.8%) was a relevant factor, impacting treatment comprehension. In terms of support, 17% of patients have a friend or family member as their primary caregiver, suggesting possible dependence on others for treatment management. Approximately 17.4% use public or private transportation to access the hospital, and 11.1% reported little or no family support. Women have less family support compared to men. Referrals to the multidisciplinary team included nutrition (7.4%), physiotherapy (3.9%), nursing (6.9%), and psychology (1.9%), highlighting the need for comprehensive and personalized care. Conclusion: The study reinforces the role of the NN in proactively identifying barriers to healthcare access, enabling targeted interventions and promoting equity. Identifying these barriers during the initial consultation is crucial to improving patient experience, reducing disparities in access to care, and enhancing clinical outcomes.

Oncology Nurse Navigator: The new look at breast cancer patients

Local
Área Exposição Pôster - 3º andar
Código
2097
Dia / Horário
8-nov.
/
10:15 - 10:45 / 16:15 - 16:45
Autor Responsável
Eunice Cristina de Souza
Tema
Breast Tumors
Forma de apresetação
Pôster
Autores
EUNICE CRISTINA DE SOUZA , DEBORA CRISTINA DE OLIVEIRA , DAYANA HIROMI BRANCATI YABASE , EDSON PRADO DE LARA , WALERIA SILVA DO NASCIMENTO , GABRIELA OLIVEIRA LUCAS PRADO LUZ
Instituições dos autores (EM ordem)
HOSPITAL SANTA CATARINA , HOSPITA SANTA CATARINA , HOSPITAL SANTA CATARINA , HOSPITAL SANTA CATARINA , HOSPITAL SANTA CATARINA , HOSPITAL SANTA CATARINA
Resumo
Introduction: Patient navigation is carried out in a humanised way, starting with the nursing consultation, addressing the side effects of the treatment to be carried out and its management, scheduling guidance on starting treatment, communication with the entire multi-professional team, such as the nutritionist and, if necessary, the psychology service. The nurse navigator aims to ensure continuity of treatment inside or outside the oncology unit (as long as the patient is in our institution), validates all medical prescriptions (triple-check stage) and monitors the administration of antineoplastic therapy when administered outside the oncology unit (intensive care unit, inpatient unit, surgical centre). The Nurse Navigator also registers, monitors results, advises and refers patients for genetic testing on platforms sponsored by pharmaceutical companies. Objectives: To establish a navigation protocol for breast cancer patients at Santa Catarina Hospital. Methodology: This is a bibliographic survey, from June to October 22, using the following databases: BIREME, LILACS, PubMed, comprising 12 studies followed by descriptive observational research. This made it possible to create a protocol to better target the public. Inclusion criteria: primary diagnosis of breast cancer. non- metastatic, female, aged between 20 and 60. The following were excluded: starting treatment at another service, palliative, loss of source of payment, tumour recurrence. Results: To assess whether the stipulated goals were achieved after the initial interventions. Conclusion: In the care of oncological patients, the role of the nurse navigator is very relevant, both for the patient and for the multi-professional team, the navigator acts as a facilitator in the process as a whole. Knowing that the nurse's work process is focussed on care and on assisting the patient in all their dimensions (physical, emotional, psychosocial and family). It is clear from this study that the implementation of Navigation Programmes guided by a well-defined protocol for the profile of the patient to be navigated, with the nurse as an actor in the coordination of care and continuous care, provides patients, services and the health system with a differential in terms of quality of care.

Oncolytic Viral Therapy with Zika: A Promising Alternative for Glioblastoma Treatment

Local
Área Exposição Pôster - 3º andar
Código
1743
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
LARISSA MARIA MORAES RODRIGUES DE SOUZA
Tema
Innovation in Healthcare
Forma de apresetação
Pôster
Autores
Larissa Maria Moraes Rodrigues de Souza , Luiza Neves Favero , Stephanie Zarlotim Jorge , Maria Luiza Aparecida de Souza , Nicolle D'ivanenko , Giovanna Soares Correa , Giovanna Silva Mucciolo , Marina do Nascimento Alves , Sofia Dutra Morais , Carolina de Carvalho Furquim da Costa Santos , Lucas Vasquez Cevallos , Letícia Rodrigues Simon , Layaly Ayoub Silva , Beatriz Moraes e Silva , Kaylaine Vitor , Adriano Justino de Lima , Beatriz Morim Alves , Clara de Souza Carvalho , Isadora Antunes Lima , Giovanna Brandão Saliba , Rafaella Mariana Helena Paiva de Almeida , David Lana Silva , Grazielle Suhett
Instituições dos autores (EM ordem)
Universidade Nove de Julho , Universidade Santo Amaro , Universidade Nove de Julho , Universidade Nove de Julho , Universidade Nove de Julho , Universidade Santo Amaro , Universidade Nove de Julho , Universidade Nove de Julho , Universidade Santo Amaro , Universidade Santo Amaro , Universidade Santo Amaro , Universidade Nove de Julho , Universidade Santo Amaro , Universidade Municipal de São Caetano do Sul , Centro Universitário das Faculdades Associadas ao Ensino , Universidade Federal de Campina Grande , Universidade Cidade de São Paulo , Faculdade São Leopoldo Mandic , Universidade Nove de Julho , Faculdade São Leopoldo Mandic , Universidade Nove de Julho , Universidade Municipal de São Caetano do Sul , Centro Universitário das Américas
Resumo
Introduction: The glioblastoma multiforme (GBM) is a malignant brain tumor that affects the central nervous system (CNS) and contains cancer stem cells (GSCs), which are resistant to conventional treatments such as surgery, radiotherapy, and chemotherapy, contributing to its recurrence. Therefore, new methods such as immunotherapy with oncolytic viruses are being investigated. The Zika virus (ZIKV) has demonstrated oncolytic potential against GSCs by infecting them and inducing an antitumor response. Studies indicate that ZIKV can lyse GBM cells, promoting tumor cell death without damaging healthy cells, and also activate the patient’s immune system, offering a promising and less toxic approach for treatment. Objectives: Evaluate viral therapy with ZIKV as a promising alternative for the treatment of glioblastoma and the remaining challenges in the use of this new approach. Methodology: A literature review was conducted in the PUBMED database, focusing on articles about oncolytic viral therapy with ZIKV for glioblastoma treatment. The descriptors “oncolytic viral therapy”, “Zika virus” and “glioblastoma” were used, including publications from 2017 onwards. Results:The inoculation of ZIKV strains in animal models with glioblastoma resulted in delayed tumor growth. Intracerebral administration is a ZIKV vaccine in mice inhibited glioblastoma progression without severe effects; the treatment enhanced the efficacy of anti-ligand immunotherapy. ZIKV infected GBM stem cells and inhibits in vitro proliferation, with 60% strain infection post-inoculation. Among the infected cells, 90% expressed the GSC marker (SOX2). Conclusion: Research in mice shows that ZIKV is promising as an oncolytic virus for the treatment of glioblastoma. ZIKV exhibits high selectivity for GBM stem cells and their markers SOX2 and integrin αvβ5, with low toxicity to non-tumor cells. Additionally, it increases the recruitment of T and myeloid cells, promoting a better immune response against the tumor and potentially be used in combination with chemotherapy. Future studies should evaluate clinical challenges, such as possible adverse effects in humans and the need for tests to determine previous exposure to ZIKV and the expression of SOX2 in tumor cells.

Osteosarcoma in Children: From Etiology to Treatment.

Local
Área Exposição Pôster - 3º andar
Código
1771
Dia / Horário
8-nov.
/
10:15 - 10:45 / 16:15 - 16:45
Autor Responsável
Julia Isume
Tema
Sarcomas
Forma de apresetação
Pôster
Autores
Gaia Marino , Julia Isume , Luana Caetano Porpino Batista , Yasmin da Silva Moura , Letícia Hanna Moura da Silva Gattas Graciolli , Arthur Guilherme Dias Oliveira , Gabriele Santos Medeiros , Gabriel Silva de Oliveira , Marina Vergara Thomazzoni , Letícia Lohanna da Silva Lima , Filipe Silvério Silva , Gabriela Bravo dos Santos , Júlia Costa Pessanha , Laíssa Costa Pessanha
Instituições dos autores (EM ordem)
Universidade Nove de Julho (UNINOVE) , Universidade Federal do Estado do Rio de Janeiro (UNIRIO) , Universidade Nove de Julho (UNINOVE) , Universidade Salvador (UNIFACS) , Faculdade de Medicina de Jundiaí (FMJ) , Faculdade Ciências Médicas de Minas Gerais (FCMMG) , Universidade Nove de Julho (UNINOVE) , Universidade Nove de Julho (UNINOVE) , Universidade de Santo Amaro (UNISA) , Universidade Nassau (Unissau) , Faculdade Santa Marcelina , Universidade da Cidade de São Paulo , Universidade Federal do Estado do Rio de Janeiro (UNIRIO) , Universidade Federal Fluminense (UFF)
Resumo
Introduction: Osteosarcoma is the most common bone tumor in children and adolescents, typically occurring during growth. It mainly affects the knee joint but can also involve the femur and tibia. Its development is influenced by programmed cell death mechanisms. Symptoms include pain, swelling, and fractures, leading to systemic issues such as weight loss and anemia. Biopsy is the most accurate diagnostic and therapeutic tool. Osteosarcoma is a primary neoplasm, rare in soft tissues, with a metastasis rate over 85%, potentially affecting the lungs, liver, and brain. Early diagnosis and treatment are crucial, highlighting the need for studies on its nature and therapy. Methodology: This integrative literature review searched PubMed and BVS databases for articles using "osteosarcoma," "pediatric," and "treatment" from 2019 to 2024. Sixteen articles were found, with thirteen included in the study. Results: Pathophysiology remains unclear, but dysfunctional apoptotic pathways are linked to development (N=2), with therapeutic approaches targeting these pathways being promising. Accelerated bone growth in adolescents (N=1) and high birth weight (N=2) are associated with higher neoplastic risk. Poor prognosis correlates with lactate dehydrogenase >1000 IU/ml, necrosis index <90, and metastasis, mainly pulmonary (N=2). Recommended treatments include tumor removal surgery, radiotherapy, and multi-agent chemotherapy, with adjuvant chemotherapy improving survival compared to surgery alone. Medical failures, unclear signs, and delays, especially in Brazil, worsen prognosis. A study found that 50% of patients end with amputation. Conclusion: Osteosarcoma is aggressive and requires early diagnosis for better prognosis. Investigate bone pain, swelling, and functional limitations with radiological exams. Biopsy should follow detailed evaluation in uncertain cases. Multimodal treatment with neoadjuvant chemotherapy, limb-sparing resection, and radiotherapy offers the best cure chances, especially in specialized centers. The lack of precise biomarkers highlights the need for further research to develop effective classification systems and new agents. Advancements in diagnosis and treatment are essential for improving outcomes.

Otoprotective measures for Cisplatin-induced toxicity in chemoradiotherapy for head and neck cancer patients: a systematic review.

Local
Área Exposição Pôster - 3º andar
Código
2023
Dia / Horário
9-nov.
/
10:15 - 10:84
Autor Responsável
Katia Regina Marchetti
Tema
Head and Neck Tumors
Forma de apresetação
Pôster
Autores
Katia Regina Marchetti , Leonardo Duarte Guerra , Pedro Angelo Luzini Gondim , Gilberto de Castro Junior
Instituições dos autores (EM ordem)
ICESP - Instituto do Câncer do Estado de São Paulo , Hospital de Base do Distrito Federal , Hospital de Base do Distrito Federal , ICESP - Instituto do Câncer do Estado de São Paulo
Resumo
This systematic review was conducted to identify otoprotective measures and treatments for ototoxicity induced by high-dose Cisplatin-based concurrent chemoradiotherapy (CRT) administered as adjuvant, or definitive, therapy in head and neck cancer (HNC) patients. The review was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed Central, Medline, and SciELO databases were used as sources in March 2024. The inclusion criteria were prospective or retrospective cohort studies, case-control studies, and phase II or III trials published in English, with full-text availability, which analyzed ototoxicity following otoprotective measures or treatments in high-dose Cisplatin-based CRT (100 mg/m² intravenous every 21 days) for HNC patients. Article selection was performed independently by three analysts, covering database searches, duplicate removal, and relevant article selection. Out of 216 initially identified articles, 11 were assessed in the final analysis: four involving low-dose Cisplatin-based CRT (three at 40 mg/m² IV weekly and one at 20 mg/m² IV weekly), three utilizing high-dose intra-arterial Cisplatin-based CRT and Sodium Thiosulfate, one study with intratympanic Sodium Thiosulfate administered before high-dose Cisplatin-based CRT, one involving Nedaplatin-based CRT, one with intratympanic Dexamethasone prior to weekly Cisplatin-based CRT, and one with Acetylcysteine administered before high-dose Cisplatin-based CRT. Most intervention did not show a statistically significant reduction in ototoxicity compared to high-dose Cisplatin-based CRT alone. Statistically significant reductions in ototoxicity were observed in only one out of the three studies using high-dose intra-arterial Cisplatin-based CRT with Sodium Thiosulfate, the study with Nedaplatin-based CRT, and the study with intratympanic Dexamethasone prior to weekly Cisplatin-based CRT. The only strategy demonstrating lower ototoxicity rates and comparable survival outcomes to high-dose Cisplatin-based CRT was low-dose Cisplatin-based CRT. Our systematic review identified a limited number of studies on otoprotective measures for high-dose Cisplatin-based CRT, with most studies showing negative results, small patient populations, and low-quality standards. The only measure showing a trend toward reducing ototoxicity while maintaining similar survival data to the high-dose Cisplatin-based CRT was the use of low-dose Cisplatin-based CRT.

Overall survival of child and adolescents with cancer in a Southeastern Brazilian state

Local
Área Exposição Pôster - 3º andar
Código
1905
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Luís Carlos Lopes-Júnior
Tema
Onco-Hematology
Forma de apresetação
Pôster
Autores
Luís Carlos Lopes Júnior , Jonathan Grassi , Wesley Rocha Grippa , Raphael Manhães Pessanha , Luiz Claudio Barreto Silva Neto , Karla Anacleto de Vasconcelos , Regina Aparecida Garcia de Lima
Instituições dos autores (EM ordem)
Universidade Federal do Espírito Santo (Ufes) , Universidade Federal do Espírito Santo (Ufes) , Universidade Federal do Espírito Santo (Ufes) , Universidade Federal do Espírito Santo (Ufes) , Universidade Federal do Espírito Santo (Ufes) , Universidade Federal do Espírito Santo (Ufes) , Universidade de São Paulo
Resumo
Introduction: Survival of children and adolescents with cancer might be correlated with the level of socioeconomic and social development. Accurate data are crucial for health policy planning and improvement of outcomes. Objective: The purpose of this study was to analyze overall survival at 1, 2, and 5 years after childhood cancer in a Southeastern Brazilian state and identify associated factors. Methods: The study cohort included all patients diagnosed with cancer before the age of 19 years and forwarded to the reference center hospital for the treatment of childhood cancer located in the southeastern region of Brazil, between January 2007 and December 2015. For 5-year survival, the Kaplan-Meier and LogRank methods were used, in addition, the Cox proportional hazards model for specific cause of death was calculated in the multivariate analysis. Results: Among 960 referred patients, all of them were followed-up for 5 years. The overall five-year survival was 76% (95%CI: 73.679.0) at 1 year, 69% (95%CI: 66.572.4) at 2 years, and 62% (95%CI: 58.765.0) at 5 years. Girls had a 28% lower risk of dying from cancer in 5 years compared to boys (HR=0.72; 95%CI: 0.5790.901; p=0.004). The highest survival rates were found for individuals with Hodgkin lymphomas 87.6% (95%CI: 78.8-97.4). The lowest 5-year survival rates were observed for patients with acute myeloid leukemia 40.8% (95%CI: 30.8-54.1). Individuals diagnosed with lymphomas (HR=0.31, 95%CI: 0.190.49; p<0.001) had a better 5-year survival than those with leukemias. Pediatric patients diagnosed with CNS tumours had 13% more risk of specific mortality by CNS tumours than those diagnosed with leukemia (HR=1.13, 95%CI: 0.831.53; p<0.434). Conclusion: We observed a lower overall survival of children and adolescents with cancer in a region of Brazil when compared to high-income countries, which was associated with sex and diagnostic groups. Childhood cancer survival is closely related to socioeconomic context. Some approaches can result in better survival rates, such as investing in public education, improved training of health professionals, investing in the detection of childhood cancer, strengthening and access to oncology services, clinical research and international cooperation.

Overview of breast Cancer in the Brazilian Public Health System

Local
Área Exposição Pôster - 3º andar
Código
1847
Dia / Horário
9-nov.
/
10:15 - 10:65
Autor Responsável
Catherine Moura da Fonseca Pinto
Tema
Disparities/Health Equity
Forma de apresetação
Pôster
Autores
Janaína Rosenburg Gioseffi , Fernanda Cristina dos Santos Simão , Nina Melo , Mariana Lorencinho , Fábio Fedozzi , Catherine Moura
Instituições dos autores (EM ordem)
Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia , Instituto Avon , Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia
Resumo
Introduction: Breast cancer is the most common neoplasm in women, being a public health problem due to its high incidence and morbimortality. The aim of the study is to provide an overview of breast cancer care in the SUS between 2015 and 2022. Methods: Descriptive study with data from the SUS Information Systems and the INCA Cancer Hospital Registry for ICD-10 C50 between 2015 and 2022. Results: Between 2015 and 2022, approximately 18 million screening mammograms were performed for women aged 50 to 69 by the SUS, with costs exceeding 800 million reais. During the Covid-19 pandemic, there was a significant reduction in the number of mammograms performed, with a 41.5% drop in 2020 and 18.9% in 2021 compared to 2019. In 2022, there was an increase of just over 1% in the number of mammograms compared to 2019. About 38% of breast cancer diagnoses occurred at advanced stages (3 and 4). Acre and Roraima had the worst staging outcomes (56%), while Rio Grande do Sul and São Paulo had the lowest percentages of diagnoses at stages 3 or 4. The average time between the first consultation and diagnosis was 34 days, with about 33% of cases taking more than 30 days for confirmation. Sergipe and Amazonas had the worst performances in the time to diagnosis. The average time between diagnosis and the start of treatment was 179 days, with Sergipe and Rondônia being the states with the worst performance. Between 2015 and 2022, nearly 532 thousand Hospitalization Authorizations were reported, with a total cost of over one billion reais. About 14 million high-complexity procedures for breast cancer treatment were performed, with about 400 thousand of radiotherapy and the rest of chemotherapy, with total costs close to five billion reais. There was a significant reduction in the number of radiotherapy procedures over the period. The number of deaths from breast cancer reached 140,589. São Paulo recorded the highest number of deaths, followed by Rio de Janeiro. Discussion and conclusion: Brazil faces challenges in the diagnosis and treatment of breast cancer, despite the 30 and 60-day laws and the National Policy for Cancer Prevention and Control. The Covid-19 pandemic worsened the situation, reducing the number of mammograms, hospital capacity, and diagnoses, highlighting the urgent need to improve access to health services and the prognosis of the disease.

PARP Inhibitor in Oncology: A Comprehensive Analysis of Mechanisms and Therapeutic Applications in Ovarian Cancer, Non-Ovarian Gynecologic Cancers, Breast Cancer and Prostate Cancer

Local
Área Exposição Pôster - 3º andar
Código
1755
Dia / Horário
9-nov.
/
10:15 - 10:69
Autor Responsável
LARISSA MARIA MORAES RODRIGUES DE SOUZA
Tema
Innovation in Healthcare
Forma de apresetação
Pôster
Autores
Larissa Maria Moraes Rodrigues de Souza , Hugo Cordeiro da Silva , Rodrigo Kfuri Carneiro , Victória Recidivi e Silva , Nathan Da Rosa Gonçalves Moreira , Samuel Fonseca Melo , Izabella Finarde , Cláudia Regina dos Santos Fortes. , Karolina de Sá Barros , Pablo Lorran Pereira Santos , Eduardo Henrique Cavalcanti Lira Gomes , Evellyn Vieira Braga do Nascimento , Manuela Rodrigues Benez , Josiane de Souza Bezerra , Debora de Paula de Araujo , Aimèe Letícia Bonifácio , Ana Carolina Fiorio de Barros , Maria Eduarda Araújo Tomaz De Lima , Gabrielli Amorim Sampaio , Tamires Mendes Fidelis , Grazielle Suhett , Stephanie Zarlotim Jorge
Instituições dos autores (EM ordem)
Universidade Nove de Julho , Universidade Nove de Julho , Faculdade Santa Marcelina , Centro Universitário Lusíada , Universidade Nove de Julho , Universidade Nove de Julho , Universidade Anhembi Morumbi , Universidade Paulista , Universidade Santo Amaro , Universidade de Santo Amaro , Universidade Nove de Julho , Universidade Nove de Julho , Anhembi Morumbi , Universidade Nove de Julho , Universidade Nove de Julho , Universidade Nove de Julho , Faculdade Santa Marcelina , Faculdade De Medicina nova esperança , Universidade Santo Amaro , Universidade Nove de Julho , Centro Universitário FAM , Universidade Nove de Julho
Resumo
BACKGROUND:The poly-ADP ribose polymerase inhibitors (PARPi) are antineoplastic drugs highlighted in the treatment of neoplasms with mutations in the BRCA1/2 genes. The PARPi prevents double-strand break repair, which causes irreversible DNA damage, leading to cell death.OBJECTIVE: This study aimed to analyze the mechanisms and therapeutic applications of PARP inhibitors as a potential therapeutic option for the treatment of ovarian, no-ovarian gynecologic, breast and prostate cancers. METHODS: A literature review was done, including searches in the SciELO and PubMed databases using the keywords "PARP inhibitor", "Treatment" and "Cancer" with the boolean operator "AND". The selected articles include topics related to ovarian, non-ovarian gynecologic, breast or prostate cancers. RESULTS: PARP inhibitors demonstrate significant benefits in the treatment of gynecologic cancers, breast cancer, and ovarian cancer. In non-ovarian gynecological cancers, drugs like Niraparib and Dostarlimab improved progression-free survival (PFS) compared to chemotherapy, with a hazard ratio (HR) of 0.60 (95% CI, 0.43–0.82; p=0.007). The combination of Durvalumab and Olaparib also showed favorable results, presenting a median PFS of 15.1 months, superior to the 9.6 months achieved by chemotherapy, with an HR of 0.55 (95% CI, 0.43–0.69; p<0.0001). In BRCA1/2 breast cancer, PARP inhibitors prolonged PFS, with an HR of 0.72 in patients previously treated with platinum and 0.68 in treatment-naive patients. In ovarian cancer, PARP inhibitors showed an HR of 0.46 in newly diagnosed patients and 0.36 in patients with BRCAm mutations. Although PARP inhibitors are generally well tolerated, there is an increase in hematological adverse events, including anemia (relative risk [RR] of 14.26), thrombocytopenia (RR of 6.86), and neutropenia (RR of 4.33). CONCLUSION: PARP inhibitors emerge as a promising therapeutic approach in the treatment of gynecologic, breast and ovarian cancers. Data reveal that PARPi, such as Niraparib, Dostarlimab and Olaparib, provide improvements in PFS, especially in patients with mutations in the BRCA1 and BRCA2 genes. Although PARP inhibitors are generally well-tolerated, there is an increase in hematological adverse events. Thus, the continuity of research and the optimization of the use of these agents are essential to maximize their clinical benefits and minimize adverse effects.

PATIENT NAVIGATION MODELS IN BRAZIL FROM THE PERSPECTIVE OF ONCOLOGY MANAGERS

Local
Área Exposição Pôster - 3º andar
Código
1835
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Glauciene Cavalcante Gomes
Tema
Nursing in Clinical Oncology
Forma de apresetação
Pôster
Autores
Glauciene Cavalcante Gomes , Juliana Pompeu Pecoraro , PATRICIA DOS SANTOS CLARO FULY , SÔNIA REGINA DE SOUZA , THAYANE DE FATIMA DA COSTA MORAES
Instituições dos autores (EM ordem)
UNIRIO , Universidade Federal Fluminense , Universidade Federal Fluminense , UNIRIO , UNIRIO
Resumo
Introduction: In the Brazilian context, the Ministry of Health has been investing efforts to address the increasing demand for oncology treatment in the country. Among the various suggested strategies, the implementation of navigation programs stands out. Currently, different models of these programs adapted to institutional realities both hospital-based and outpatient are observed. Objective: To describe the models of patient navigation programs implemented from the perspective of healthcare managers. Methods: This descriptive study with a qualitative approach employed the snowball sampling method for participant recruitment. The study was approved by the Research Ethics Committee (approval report nº 5.908.102). Data analysis was conducted using thematic analysis as per Minayo. Results: Healthcare managers with navigation programs implemented for over a year participated in the study. These programs are more prevalent in the Southeast and South regions and are more frequent and structured within the supplementary network in the outpatient setting. Key attributes include coordination with other institutions, care coordination, and elimination of barriers, which facilitate and optimize the care flow. Barriers mentioned include changes in care culture, navigator nurse training, lack of scaling guidelines, and the absence of a guiding flow for implementation and maintenance. Conclusion: This research is relevant for clinical practice, education, research, and management. It contributes to a situational diagnosis of navigation programs in Brazil, highlighting that despite public policies, patient navigation remains scarce within the SUS (Sistema Unico de Saúde). The development of models and strategies is recommended to guide all aspects of navigation and expand programs throughout Brazil.

PEDIATRIC ONCOLOGY NURSING IN LATIN AMERICA AND THE CARIBBEAN: SCOPE OF PRACTICE

Local
Área Exposição Pôster - 3º andar
Código
1944
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Luís Carlos Lopes-Júnior
Tema
Nursing in Clinical Oncology
Forma de apresetação
Pôster
Autores
Luís Carlos Lopes-Júnior , Edmara Maia , Regina Aparecida Garcia de Lima
Instituições dos autores (EM ordem)
Universidade Federal do Espírito Santo (Ufes) , Universidade Federal de São Paulo , Universidade de São Paulo
Resumo
Introduction: Cancer is one of the leading causes of death from disease in children and adolescents worldwide. In Latin America and the Caribbean, childhood and adolescent cancer care is highly heterogeneous, as health systems, resources, care processes, and health outcomes vary considerably among the different countries in the region. One of the main pillars of the CureAll Americas framework is strengthening centers of excellence and promoting training and good practices within the health workforce, especially among pediatric oncology nurses. Objective: The purpose of this study was to identify, systematize, and consolidate available evidence on the scope of pediatric oncology nursing practice in Latin America and the Caribbean based on essential core competencies to incorporate them into clinical practice, teaching, and research. Methods: A scoping review was undertaken following the JBI recommendations in order to find the best evidence for pediatric oncology nursing practice. Patient- and family-centered care and the conceptual model of competencies for teenagers and young adults with cancer, developed by the Teenage Cancer Trust, were used as the theoretical foundations for systematizing the recommendations. Results: The process of creating competencies for nurses caring for adolescents and young people with cancer was based on six domains: 1) clinical and supportive care; 2) education and research; 3) engagement, advocacy, and promotion; 4) interprofessional team and the journey of the child or adolescent with cancer and their family; 5) leadership and professional development and 6) development of health services and policies. Conclusions: This research compiles and systematizes recommendations to support pediatric oncology nursing practice centered on caring for children and adolescents with cancer, as well as their families. It can also be used by institutions, professional associations, managers, and public policymakers to help establish essential competencies for pediatric oncology nursing practice in Latin America and the Caribbean

PERCEPTION OF THE MULTIPROFESSIONAL TEAM ABOUT THE CHALLENGES FOR EARLY PALLIATIVE CARE IN ONCOLOGY

Local
Área Exposição Pôster - 3º andar
Código
1726
Dia / Horário
9-nov.
/
10:15 - 10:91
Autor Responsável
Ceci Figuerêdo da Silva
Tema
Nursing in Clinical Oncology
Forma de apresetação
Pôster
Autores
Ceci Figuerêdo da Silva , Elaine Guedes Fontoura
Instituições dos autores (EM ordem)
Grupo Oncoclinicas , Universidade Estadual de Feira de Santana
Resumo
Introduction: Palliative care is an emerging form of assistance, built within a model of total, active and comprehensive care offered to patients and their families. Although this practice is often linked to the proximity of death, studies have shown the benefit of early introduction of this care with active cancer treatments. Objective: to describe the perception of the multiprofessional team about the challenges for the early introduction of palliative care in people with oncological problems. Method: qualitative study, with a phenomenological approach, based on the theoretical-philosophical framework of Viktor Frankl. It was developed with the multiprofessional team in a unit specialized in oncological assistance located in the city of Salvador, through a phenomenological interview, after approval by the Research Ethics Committee. Data were analyzed using the phenomenological method proposed by Martins and Bicudo. Eight professionals from the multiprofessional team participated, including one physician, two nurses, one pharmacist, two psychologists, and two nutritionists. Results: two categories emerged: Lack of knowledge of the multiprofessional team members; Association between palliative care and end of life. There is a gap in knowledge about palliative care among health professionals and this was considered a challenge for early introduction. Palliative care is often associated with the end of life and refers to feelings of fear and hopelessness. The testimonies revealed the need to deconstruct the association of palliative care and the end of life, which focuses on improving quality of life at any stage of coping with the disease. Conclusion: The multiprofessional team realizes that the early palliative care brings many benefits to patients and their families, but for its introduction of palliative care since the oncological diagnosis, it is necessary to overcome the barrier of lack of knowledge of the health team, especially the physician, who acts in the referral of eligible patients to a team specialized in palliative care. The theme of death and dying in this context needs to be discussed more reflectively, so that it is possible to demystify the idea that palliative care are associated with the end of life.

PHENOTYPE AND GENOTYPE OF PATIENTS WITH LI-FRAUMENI SYNDROME TREATED AT A REFERENCE CLINIC IN THE ZONA DA MATA MINEIRA

Local
Área Exposição Pôster - 3º andar
Código
1962
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Débora Nogueira Coelho Dias
Tema
Oncogenetics
Forma de apresetação
Pôster
Autores
Débora Nogueira Coelho Dias , Eduarda Silva Kingma Fernandes , Lívia Maria Ferreira Sobrinho , Maria Paula Miscoli Estevam , Virginia Salles de Oliveira Barra , Leonardo Hansen Laranja , Tiago Baesso Monteiro de Castro , Vitória Batista Clemente , Letícia Drumond de Abreu Guimarães , Monique Oliveira Freitas , Milton Prudente
Instituições dos autores (EM ordem)
Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica , Universidade Federal de Juiz de Fora , Neoclinica Oncologia e Genetica , Neoclinica Oncologia e Genetica
Resumo
Introduction: Approximately 10% of cancers are conected to hereditary predisposition syndromes, which increase the risk of developing tumors throughout life. Among the known predisposition syndromes, Li-Fraumeni Syndrome (LFS) has autosomal dominant inheritance and, in most affected individuals, is caused by germline variants in the TP53 gene. FIrst described by Li and Fraumeni in 1969, LFS predisposes to several cancers, including breast cancer, oral cancer, central nervous system tumors, bone and soft tissue sarcomas, adrenal carcinoma and leukemia. Objective: Describe the phenotypes and genotypes of patients with germline variants in the TP53 gene, affected of Li-Fraumeni syndrome in the Zona da Mata, region of Minas Gerais. Methods: Cross-sectional study with a cohort of patients who performed genetic testing and counseling with a geneticist at an oncology and genetics clinic between 2016 and 2024. Patients with positive results for TP53 were included, and a descriptive analysis of phenotypes (race, age, sex, câncer history) and genotypes (genetic variants found) was performed. Results: The sample consisted of 21 patients with a mean age of 51 years (ranging from 31 to 67 years), 90% of whom were female. Regarding race, 60% were leucoderms and 40% were melanoderms. The analysis revealed the presence of two main variants: TP53 c.1010G>A (p.Arg337His) and TP53 c.467G>A (p.Arg156His). Among the frequencies observed, the TP53 (p.Arg337His) variant was the most prevalent, found in 80% of patients, and the TP53 (p.Arg156His) variant was found in 20% of patients. The P.Arg156His variant is classified as a Variant of Uncertain Significance (VUS) according to the Variant Classification criteria of the American College of Medical Genetics. However, the patients presented a clinical phenotype suggestive of the syndrome (met the Chompret criteria), making it possible to reclassify the variant as probably pathogenic. Sixty-six percent of patients had a personal history of cancer, 52% breast cancer, 4% ovarian cancer, a type usually not related to LFS and 9% prostate cancer. Conclusion: The identification of these variants is crucial for the development of personalized management and treatment strategies. These findings highlight the importance of genetic sequencing in the molecular characterization of LFS and in the guidance of therapeutic approaches.

PRECLINICAL STUDY OF CURCUMIN WITH DOXORUBICIN IN MURINE BREAST CANCER CELLS

Local
Área Exposição Pôster - 3º andar
Código
1768
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Gustavo de Souza Gomes
Tema
Breast Tumors
Forma de apresetação
Pôster
Autores
Gustavo de Souza Gomes , Carlos Luan Alves Passos , Christian Ferreira , Jerson Lima da Silva , Eliane Fialho de Oliveira
Instituições dos autores (EM ordem)
Instituto de Nutrição Josué de Castro, INJC/UFRJ, RJ, Brazil , Instituto de Nutrição Josué de Castro, INJC/UFRJ, RJ, Brazil , Instituto de Nutrição Josué de Castro, INJC/UFRJ, RJ, Brazil , Instituto de Bioquímica Médica Leopoldo de Meis, IBqM/UFRJ, RJ, Brazil , Instituto de Nutrição Josué de Castro, INJC/UFRJ, RJ, Brazil
Resumo
INTRODUCTION: Breast cancer is highly heterogeneous and includes different phenotypic and morphological types that define therapeutic conduct. In this meaning, murine mammary carcinoma cells models are fundamental to comprehend tumor growth, as the therapeutic response to new anticancer drugs that can be used in future treatments. OBJECTIVES: The aim of this study was to investigate the effect of curcumin, a polyphenol found in the Curcuma longa L., in association with Doxorubicin, a traditional chemotherapic in murine triple-negative breast cancer cell line 4T1. MATERIAL AND METHODS: The viability of 4T1 cells was evaluated using the MTT assay. The phases of the cell cycle were analyzed in flow cytometry after labeling with RNAse-propidium iodide (PI). The morphological characteristics were analyzed with Giemsa stain. The characterization of cell death was investigated by labeling with PI and Annexin-V. The mitochondrial membrane potential (ΔΨm) and the detection of reactive oxygen species (ROS) were analyzed by flow cytometry after labeled the cells with JC-1 and DCFDA, respectively. RESULTS: Curcumin and doxorubicin had a cytotoxic effect in 4T1 cells, after 24 and 48 hours of treatment, with IC50 values of 120.5 µM and 38.75 µM for curcumin and 8.05 µM and 5.83 µM for doxorubicin, respectively. The association of 18.99 µM curcumin with 0.36 µM of doxorubicin showed synergistic effect in the inhibition of 4T1 cell growth after 48 hours of treatment. Besides, this association decreases of 16-fold the concentrations of doxorubicin. Morphological analyses of 4T1 cells demonstrated alterations in the presence of curcumin and doxorubicin alone or in association. Curcumin decreases ROS production and alters the ∆ᴪM. Curcumin decreases G0/G1 phases, and the association of curcumin and doxorubicin decreases G0/G1 phases and increases the S and G2/M phases. The association increased the number of PI-labeled cells, which characterizes death by necrosis. In addition, in vivo murine trials are ongoing. CONCLUSION: Curcumin treatment demonstrated a significant effect alone or in combination with doxorubicin in vitro, suggesting a new potential therapeutic approach that can reduces the doses of isolated traditional compounds and minimize adverse effects of the treatments.

PREVALENCE OF HER2 LOW BREAST CANCER IN A SOUTH BRAZILIAN REFERENCE HOSPITAL - a real world data base

Local
Área Exposição Pôster - 3º andar
Código
1955
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Gabriel Ben Bordinhão
Tema
Breast Tumors
Forma de apresetação
Pôster
Autores
Alessandra Notari , Gabriel Ben Bordinhão , Pietro Bica Belmonte , Gabriela Pereira Macelaro , Eduarda Paiva Borsa , Claudia Giuliano Bica
Instituições dos autores (EM ordem)
1. Programa de Pós-graduação em Patologia UFCSPA; e 2. Hospital Escola da UFPEL/EBSERH , Universidade Federal de Ciências da Saúde de Porto Alegre , Universidade Federal de Ciências da Saúde de Porto Alegre , Universidade Federal de Ciências da Saúde de Porto Alegre , Universidade Federal de Ciências da Saúde de Porto Alegre , 1. Programa de Pós-graduação em Patologia UFCSPA; e 2. Universidade Federal de Ciências da Saúde de Porto Alegre
Resumo
Background: The effectiveness of targeted therapy for HER2-low breast cancer is an area of ongoing research. Understanding the prevalence of HER2-low is importante for identifying patients likely to benefit from these therapies, optimizing treatment and guiding future research. In a referral hospital in southern Brazil, where many breast cancer patients are treated annually, knowing the prevalence of HER2-low in this population provides valuable insights. Methods: We conducted a retrospective review of breast cancer cases treated in 2020 at a reference hospital in southern Brazil. The study aimed to assess the prevalence of HER2-low breast cancer by analyzing patients with HER2-negative and HER2-low status on immunohistochemistry (IHC), excluding HER2-positive cases. Pathology reports and medical records from an electronic database were reviewed, and clinical and pathological findings were described by frequencies. HER2-low was defined as IHC +1 or +2 with negative in situ hybridization (ISH). The study was approved by the Institutional Review Board. Results: Of 324 breast cancer cases diagnosed in 2020, 197 were HER2 0 and HER2-low tumors (IHC 1+ or 2+ not amplified). The median age was 58.5 years (range 33-87). Of the HER2-low tumors, 89.65% were hormone receptor-positive, compared to 83.92% of HER2 0 tumors. Stage distribution was 39.5% stage I, 42.13% stage II, 15.22% stage III, and 3.04% stage IV. The prevalence of HER2-low tumors was 14.72% (29 cases), lower than recent trials. Conclusions: The 14.72% prevalence of HER2-low tumors in our study is lower than in recent trials, underscoring the need for extended research to confirm these findings. Understanding HER2-low prevalence is vital for the Brazilian population, especially given emerging therapeutic options for this subgroup.

Paired normal-tumor exome sequencing in metastatic prostate cancer: interplay between germline and somatic data

Local
Área Exposição Pôster - 3º andar
Código
1923
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Gabriel Souza Macedo
Tema
Oncogenetics
Forma de apresetação
Pôster
Autores
Gabriel de Souza Macedo , Jaqueline Bohrer Schuch , Angélica Cerveira de Baumont , Giovana Dallaio Curzel , Claudia Bordignon , Mahira Lopes Rosa , Nathan Araujo Cadore , Juliana Sena de Souza , Daniela Lacerda Costa Louzeiro , Lilian Arruda do Rego Barros , Alessandra Notari , Aline Bobato Lara Gongora , Vitor Fiorin de Vasconcellos , Williams Fernandes Barra , Henrique Guesser Ascenco , Daniel D'Almeida Preto , Juliana Janoski de Menezes , Edilmar de Moura Santos , Gustavo Werutski , Pedro Emanuel Rubini Liedke , Gláucio Antônio Bertollo , Eduardo Kowalski Neto , André Luiz Campos Mancini , Marina Bessel , Daniela Dornelles Rosa
Instituições dos autores (EM ordem)
Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital Moinhos de Vento , Hospital do Câncer do Maranhão Tarquinio Lopes Filho , Instituto Brasileiro de Controle do Câncer , Hospital Escola da Universidade Federal de Pelotas (HE- UFPEL/EBSERH) , Hospital do Câncer UOPECCAN , Hospital Universitário Cassiano Antônio Moraes (HUCAM-EBSERH-UFES) , Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará , Hospital Universitário Maria Aparecida Pedrossian , Hospital de Câncer de Barretos , Hospital Nossa Senhora da Conceição , Liga Norte Riograndense Contra o Câncer , Hospital São Lucas PUCRS , Hospital de Clínicas de Porto Alegre , Associação Feminina de Educação e Combate ao Câncer (AFECC), Hospital Santa Rita de Cássia , Hospital Calixto Midlej Filho, Santa Casa de Misericórdia de Itabuna , Hospital Universitário Getúlio Vargas (HUGV/EBSERH) , Hospital Moinhos de Vento , Hospital Moinhos de Vento
Resumo
Introduction: Metastatic castration-resistant prostate tumors with mutations in homologous recombination repair (HRR) genes are vulnerable to the action of poly-ADP ribose polymerase inhibitors. Germline and somatic variations are intricately connected and together shape tumor initiation and progression, but their role in cancer, especially in a mixed ancestry population, remains poorly characterized. Aim: We performed a large-scale prospective exome sequencing of matched tumor-blood samples from 193 Brazilian patients diagnosed with metastatic prostate cancer(PC), coupled with clinical annotation and genetic ancestry, to define the germline and somatic genomic landscape in our population. Methods: This is a multicenter study, approved by the ethics committees, encompassing men with metastatic PC from all Brazilian regions. Germline DNA was extracted from blood and tumor DNA from formalin-fixed paraffin-embedded (FFPE) tissue. Whole-exome sequencing was performed, and genetic variants were interpreted according to specific guidelines. Results: Pathogenic (PV) and likely pathogenic (LPV) germline variants were identified in 14.5% of patients, of which 5.7% were in genes significantly associated to higher risk for PC. PV and LPV in CHEK2, ATM, BRCA2 and PALB2 genes were the most common, all representing 18.1% of the mutated-genes. The median age at diagnosis was 3 years earlier in PV and LPV carriers (61 years, 60.0-70.5) compared to non-carriers (64 years, 55.0-63.7) (p-value=0.032). Likely clonal hematopoiesis of indeterminate potential variants were identified in 7.8%(n=15), mainly affecting DNMT3A and TET2 genes. In contrast to germline data, somatic results were obtained in 61(31.6%) of the samples. The most frequently mutated genes were TP53 (27.9%), SPOP (14.8%), GNAQ (11.5%), APC (8.2%), ATM(8.2%) and PTEN(8.2%), being mainly mutually exclusive. Overall, HRR mutations were identified in 18.2% of the cases, most of them showed the inactivation of the second allele within the tumor. The mean tumor mutational burden was 3.7 (±4.5) mutations/Mb and 8.3% (n=5) samples showed more than 10 mutations/Mb. Conclusion: To our knowledge, this is the first Brazilian study to perform comprehensive genomic analyses in patients with metastatic prostate cancer from different regions of the country. Our data demonstrate a low prevalence of PV and LPV in genes associated to PC risk and highlight the difficulties when working with exome on FFPE samples.

Palliative Treatments of Malignant Dysphagia in Patients with Esophageal Cancer: A Systematic Review

Local
Área Exposição Pôster - 3º andar
Código
1884
Dia / Horário
8-nov.
/
10:15 - 10:45 / 16:15 - 16:45
Autor Responsável
Marina Silveira Torres
Tema
Palliative Care, Support and End of Life
Forma de apresetação
Pôster
Autores
Marina Silveira Torres , Igor Pimentel Nogueira , Giovanna Lima Emerick , Helena Paganelli Machado da Costa , Tarsila Campanha da Rocha Ribeiro
Instituições dos autores (EM ordem)
Faculdade de Ciências Médicas e da Saúde de Juiz de Fora , Faculdade de Ciências Médicas e da Saúde de Juiz de Fora , Faculdade de Ciências Médicas e da Saúde de Juiz de Fora , Faculdade de Ciências Médicas e da Saúde de Juiz de Fora , Faculdade de Ciências Médicas e da Saúde de Juiz de Fora
Resumo
Background. Esophageal cancer is the eighth most prevalent cancer in the world and it is frequently diagnosed in advanced stages. Late diagnosis justifies the high mortality rates and the relevance of palliative care. Aim. Evaluate, through a systematic review, the efficacy of malignant dysphagia‘s palliative treatments in patients with advanced esophageal neoplasms. Methods. Clinical trials and cohort studies originally published in English, in the last five years, in humans, were analyzed, taking as a reference the National Library of Medicine (MedLine), Scientific Eletronic Library Online (SciELO) and LILACS databases. The descriptors Esophageal Neoplasms, Deglutition Disorders, Palliative Care were searched through Medical Subject Headings (MeSH) on the U.S. National Library of Medicine (NLM) website. Studies with cryotherapy, chemoradiotherapy with concurrent durvalumab, short-course hypofractionated radiotherapy and biodegradable stents plus external beam radiotherapy (EBRT) were included. Studies that did not address the aim of the research were excluded. This systematic review was performed according to the PRISMA Statement. Results. Of the 708 records identified, only 6 studies were included in the final analysis after the screening. 185 participants with a mean age of 63 years old were envolved. Cryotherapy showed clinical and statistical improvement in dysphagia score from moderate to mild (p=0,004), while hypofractionated chemoradiotherapy presented a favorable response to dysphagia scores. Combined therapy with durvalumab demonstrated continuous control of this symptom. The short-course hypofractionated 2D radiotherapy showed efficacy on reduction of dysphagia’s severity in 76% of the patients (p<0,001) and no patient presented acute ≥ G3 toxicity. Unwanted outcomes were noticed in 41,7% patients that received combined therapy of biodegradable stents and external beam radiotherapy (EBRT). Conclusion. Palliative therapies presented an effective control in cases of malignant dysphagia and must be considered in patients with advanced neoplasms. However, studies with a higher volume of patients are needed and the increase of these therapies’ availability is important to allow this recommendation to be established.

Pancreatic cancer mortality: an epidemiological analysis using DATASUS

Local
Área Exposição Pôster - 3º andar
Código
2059
Dia / Horário
9-nov.
/
10:15 - 10:45
Autor Responsável
Letícia Bezerra de Almeida
Tema
Upper Gastrointestinal Tract Tumors (Stomach, Esophagus, Pancreas, Liver, Biliary Tract, Duodenum)
Forma de apresetação
Pôster digital
Autores
Letícia Bezerra de Almeida , Arthur Nóbrega Rodrigues de Lima , Henrique Fialho Carneiro Braga Costa , Bruno Varela Fernandes , Matheus Henrique Marinho de Gouveia , Hiago de Freitas Macedo , Larissa de Pontes Costa Abreu , Carla Vitória Brito dos Santos , Paulo Vinícios Morais Alexandre , Bright Owusu Ansah , Emanuella Maria Batista da Motta Pessoa , Kaline Kezia Piragibe Souto , Sywldson Marllon de Santana Moura , Isadora de Meira Melo , Catarina Ramalho dos Santos , Giulia Di Cedico Paranhos , Vicente Castor Brito , Lucas Brito Maracajá , Larissa Calixto Hespanhol , Giulia Carvalhal , Gabrielly Araújo Vilela , Edson Júnior Diniz , Maria Vitória Silva Memória , Kael Costa Santana , Luis Henrique dos Santos Medeiros , Eliel Pereira da Silva , Georgia Nóbrega de Oliveira , Lucas Miná Pinto
Instituições dos autores (EM ordem)
Universidade Federal de Campina Grande , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG , UFCG
Resumo
Introduction: Pancreatic neoplasia is a disease with a very unfavorable prognosis, since it has less than 10% survival rate in 5 years after diagnosis due to its late detection. Objective: To describe the increasing mortality rate due to pancreatic cancer. Methodology: Observational study based on data collected from the Department of Information Technology of the Unified Health System (DATASUS), using the TABNET tool. The variables used in this study were the number of deaths from pancreatic cancer in Brazil from 2012 to 2022 and the relationship of these data with race, sex, age group and place of death. Results: In this 10-year interval, a total of 115,379 deaths due to Pancreatic Cancer were observed, with females (50.3%) more affected than males (49.7%), a male-to-female ratio of 1.01-1, and in white Brazilians than black Brazilians, a different pattern found in the USA, where it is more common in men, a ratio of 1.3-1, and in blacks. As for the most affected Brazilian regions, in decreasing order: Southeast (50.5%), South, Northeast, Midwest and North. A pattern similar to that found in North America, Europe and Asia is observed, in which the most western and industrialized regions are the most affected. Regarding the age group, two peaks are found in the age range, between 60-69 (27.2% years) and 70-79 years (28%). In addition, it is noted that there is a lower prevalence before the age of 45. Conclusion: There is an evident increase in deaths due to malignant neoplasm of the pancreas and predictions that this will tend to increase in the coming years, due to the dietary pattern, with the epidemiological pattern with the highest prevalence being white women from the southeast region between 60 and 80 years old.

Pathologic Response in ER-Low Early-Stage Breast Cancer Treated with Neoadjuvant Pembrolizumab plus Chemotherapy

Local
Área Exposição Pôster - 3º andar
Código
1839
Dia / Horário
7-nov.
/
19:30 - 20:30
Autor Responsável
Renata Rodrigues da Cunha Colombo Bonadio
Tema
Breast Tumors
Forma de apresetação
Pôster
Autores
Renata Colombo Bonadio , Flávia Cavalcanti Balint , Isadora Martins de Sousa , Ana Carolina Marin Comini , Monique Celeste Tavares , Fernanda Madasi , José Bines , Rafael Dal Ponte Ferreira , Daniela Dornelles Rosa , Candice Lima Santos , Zenaide Silva de Souza , Daniele Assad-Suzuki , Júlio Antônio Pereira de Araújo , Débora de Melo Gagliato , Carlos Henrique dos Anjos , Bruna M. Zucchetti , Anezka Ferrari , Mayana Lopes de Brito , Maria Marcela Fernandes Monteiro , Renata Cangussu , Paulo M. Hoff , Maria del Pilar Estevez-Diz , Laura Testa , Romualdo Barroso-Sousa
Instituições dos autores (EM ordem)
Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , A.C.Camargo Cancer Center, São Paulo, Brazil , A.C.Camargo Cancer Center, São Paulo, Brazil , A.C.Camargo Cancer Center, São Paulo, Brazil , A.C.Camargo Cancer Center, São Paulo, Brazil , Instituto D’Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil , Instituto D’Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Serviço de Oncologia, Hospital Moinhos de Vento, Porto Alegre, Brazil , Serviço de Oncologia, Hospital Moinhos de Vento, Porto Alegre, Brazil, Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Instituto D’Or de Pesquisa e Ensino (IDOR), Recife, Brazil , Hospital Sírio-Libanês, Brasília, Brazil , Hospital Sírio-Libanês, Brasília, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Centro de Oncologia - Hospital Beneficência Portuguesa, São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Centro de Oncologia - Hospital Beneficência Portuguesa, São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Hospital Sírio-Libanês, São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , DASA Oncologia, Hospital 9 de Julho, São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Hospital Santa Paula, São Paulo, Brazil , Clínica AMO, Salvador, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Instituto do Câncer do Ceará, Fortaleza, Brazil , Instituto D’Or de Pesquisa e Ensino (IDOR), Salvador, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil , Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil , Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM) , DASA Oncologia, Brasilia Hospital, DASA, Brasília, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM)
Resumo
Background: Estrogen receptor-low (ER-low) breast cancer (BC) exhibits a tumor biology more similar to basal-like tumors than to luminal-like tumors. Despite patients with ER-low breast cancer having been excluded from the Keynote-522 study, they were included in trials evaluating neoadjuvant pembrolizumab (Keynote-526 trial) and nivolumab (CheckMate 7FL) for hormone receptor-positive BC. Although the ER-low subgroup was small, a benefit from neoadjuvant immunotherapy was suggested, with pathologic complete response (pCR) rates of 55.9% and 55.6% in the immunotherapy arms compared to 30.2% and 28.6% in the control arms, respectively. Objective: To evaluate the outcomes of ER-low BC treated with neoadjuvant P+CT. Methods: The real-world data (RWD) Neo-Real/GBECAM 0123 study is collecting data on patients with BC treated with neoadjuvant P+CT since July 2020 across ten Brazilian cancer institutions. In this analysis, we evaluated the clinical characteristics and efficacy outcomes of patients with ER-low BC, focusing on the rates of pCR and residual cancer burden (RCB) 0-1. ER-low was defined as estrogen receptor expression lower than 10% in immunohistochemistry. Results: Among 410 patients included in this cohort to date, 14 had ER-low BC; 9 (64.3%) had stage II and 5 (35.7%) had stage III disease. The median age was 39.7 years (range 28 - 61). The majority of patients had grade 3 tumors (n = 13, 92.8%), and the median Ki67 index was 77% (range 30% - 90%). Thirteen patients completed the neoadjuvant therapy and underwent surgery. Among these, 8 (61.5%) achieved a pCR. The RCB 0-1 rate was also 61.5%; all five patients (38.5%) who did not achieve a pCR had RCB 2. Among 325 patients with ER-negative BC included in the same RWD study who had already undergone surgery, the pCR rate was 62.1%. With a median follow-up of 15.6 months, one patient in the ER-low group with residual disease had a recurrence. No recurrence was observed among the ER-low patients with a pCR. Conclusion: In this cohort, ER-low BC represented a small subgroup enriched by tumors of high grade and high proliferative index. The pCR rates with neoadjuvant P+CT were comparable to those observed in TNBC. These results support the use of neoadjuvant immunotherapy for the ER-low subgroup.